Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Symtuza

Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15–16

HOS-138495 · Präparat HOS-098200

15 OTHER LIPID MODIFYING AGENTS Lomitapide Based on theoretical Co-administration is considerations, Symtuza is contraindicated (see section 4.3). expected to increase the exposure of lomitapide when co- administered. (CYP3A inhibition) H2-RECEPTOR ANTAGONISTS Cimetidine Based on theoretical Symtuza can be co-administered Famotidine considerations, no mechanistic with H2-receptor antagonists Nizatidine interaction is expected. without dose adjustments. Ranitidine IMMUNOSUPPRESSANTS Ciclosporin Based on theoretical considerations Concentration monitoring of the Sirolimus DRV/COBI is expected to increase immunosuppressive agent must Tacrolimus these immunosuppressant plasma be done when co-administration concentrations. with Symtuza occurs. (CYP3A inhibition) Co-administration of ciclosporin is expected to increase plasma concentrations of tenofovir alafenamide. (P-gp inhibition) Concomitant use of everolimus Everolimus and Symtuza is not recommended. INHALED BETA AGONISTS Salmeterol Based on theoretical considerations Concomitant use of salmeterol DRV/COBI is expected to increase and Symtuza is not salmeterol plasma concentrations. recommended. The combination (CYP3A inhibition) may result in increased risk of cardiovascular adverse events with salmeterol, including QT prolongation, palpitations and sinus tachycardia. NARCOTIC ANALGESICS/TREATMENT OF OPIOID DEPENDENCE Buprenorphine/naloxone Based on theoretical considerations Dose adjustment for DRV/COBI may increase buprenorphine may not be buprenorphine and/or necessary when co-administered norbuprenorphine plasma with Symtuza, but a careful concentrations. clinical monitoring for signs of opiate toxicity is recommended. Methadone Based on theoretical considerations No adjustment of methadone dose DRV/COBI may increase is expected when initiating methadone plasma concentrations. co-administration with Symtuza. Clinical monitoring is With ritonavir-boosted darunavir, a recommended, as maintenance small decrease in methadone therapy may need to be adjusted plasma concentrations was in some patients. observed. Consult the Summary of Product Characteristics for darunavir for further details. Fentanyl Based on theoretical considerations Clinical monitoring is Oxycodone DRV/COBI may increase plasma recommended when Tramadol concentrations of these analgesics. co-administering Symtuza with (CYP2D6 and/or CYP3A these analgesics. inhibition)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) nizatidine (HOS-138496) methadone (HOS-086198) cimetidine (HOS-085835) lomitapide (HOS-086160) oxycodone (HOS-109487) famotidine (HOS-112087) buprenorphine (HOS-086193) salmeterol (HOS-086285) tacrolimus (HOS-085202) ranitidine (HOS-085660) everolimus (HOS-086310) naloxone (HOS-109490) sirolimus (HOS-085172) fentanyl (HOS-086196) tramadol (HOS-112871)